以岭药业品牌怎么样 申请店铺

我要投票 以岭药业在中草药行业中的票数:629 更新时间:2025-11-22
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

报告:“成分党”成为美妆主流消费群体

毕马威近日发布的《"颜"值经济新篇章:2025年中国美妆市场行业报告》(以下简称《报告》)显示,据调查,58.8%的消费者将产品成分作为购买决策的首要考量因素,“成分党”成为主流消费群体。与此同时,300-500元中端价格带产品市场份额显著提升,而超低价与高端市场则双双承压,反映出消费者在追求"悦己"体验的同时,更加注重产品的实际功效与性价比。(新浪财经)

4分钟前

美联储传声筒:鲍威尔不是降息的最大障碍 美联储内部共识机制濒临瓦解

“美联储传声筒”Nick Timiraos撰文称,特朗普本周表示,他预计在明年5月任命新的美联储主席后,利率将大幅下降。然而,美联储内部反对12月降息声浪越来越大,这意味着他的愿望可能难以实现。无论鲍威尔在12月选择按兵不动还是降息,他都面临近八年任期内最严重的内部阻力。这种分歧可能延续至明年,这意味着,即便更换主席,也并不等于就能确保会有更多降息。一些人担忧,若特朗普无法如愿以偿,可能会采取更激进手段削弱央行独立性,以换取降息。(金十数据APP)

4分钟前

第八届进博会,上海合作交流采购团达成意向采购额7.12亿元

11月21日下午,第八届中国国际进口博览会上海市合作交流采购团总结展示交流活动在闵行区虹桥品汇成功举办。据介绍,本届进博会上海市合作交流采购团采购成交再创新高,共达成意向采购额7.12亿元人民币,比上届提升4.71%,累计意向采购额突破30亿元。采购团规模也进一步扩大,分团总数增至33家,共组织30批次、近760人次走进进博会参观交流,参与企业数量创历年新高。(界面新闻)

4分钟前

《哪吒2》不参加奥斯卡竞逐

当地时间11月21日,奥斯卡奖的主办方美国电影艺术与科学学院公布了符合资格参与最佳纪录长片、最佳国际影片以及最佳动画长片三个奖项竞逐的影片大名单。在最佳动画长片领域,今年有35部影片有资格“冲奥”,意外的是,《哪吒之魔童闹海》并不在其中。另一方面,《罗小黑战记2》榜上有名。(澎湃新闻)

4分钟前

IDEA研究院孵化企业视启未来获近亿元融资

36氪获悉,孵化自IDEA研究院的视觉大模型企业,视启未来(深圳)科技有限公司宣布完成近亿元天使轮融资。本轮由A股上市公司安凯微领投,昊辰资本、德虎资本、元禾璞华、银杏谷资本、力合中科、数字未来、九安智能等机构跟投。

4分钟前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询